AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

January 4, 2021 GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Jan 4, 2021--

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January.

Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m. ET.

Additionally, Mr. Iwicki will participate in a pre-recorded fireside chat as part of the H.C. Wainwright BioConnect Conference, which will be available on the Kala website beginning Monday, January 11, 2021 at 6:00 a.m. ET.

ADVERTISEMENT

To access the webcasts and subsequent archived recording of each presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY ® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and the January 2019 launch of INVELTYS ® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210104005019/en/

CONTACT: Investor Contacts:

Loraine Spreen

loraine.spreen@kalarx.com

857-277-4842Hannah Deresiewicz

hannah.deresiewicz@sternir.com

212-362-1200

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES GENETICS PHARMACEUTICAL OPTICAL BIOTECHNOLOGY

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2020.

PUB: 01/04/2021 08:00 AM/DISC: 01/04/2021 08:01 AM

http://www.businesswire.com/news/home/20210104005019/en